The 7% HbA1c obtained, which is in line with accepted diabetologic targets, is in fact not better than the results of the DCCT/EDIC trials, which showed that intensive insulin therapy resulting in mean HbA1c of∼ 7% maintained over a mean 6.5 years reduced the development and progression of early microvascular complications associated with diabetes by 34%–76% [30]. Here, INS is linked to diabetes mellitus.